Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Satsuma Pharmaceuticals aggregated by PharmaCompass.com.

    Client Virtual Booth

    SATSUMA PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Satsuma Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Oyster Point Boulevard, Suite 221, South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.satsumarx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/satsuma-pharmaceuticals-inc.
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    FDA Issues Complete Response Letter for Satsuma’s STS101
    FDA Issues Complete Response Letter for Satsuma’s STS101

    https://ssl4.eir-parts.net/doc/2395/tdnet/2381900/00.pdf

    PRESS RELEASE
    19 Jan 2024
    Share Share
    Satsuma Pharma and SNBL Announce Three Abstracts on STS101
    Satsuma Pharma and SNBL Announce Three Abstracts on STS101

    https://www.globenewswire.com/news-release/2023/06/15/2688854/0/en/Satsuma-Pharmaceuticals-and-SNBL-Announce-Three-Abstracts-on-STS101-for-the-Acute-Treatment-of-Migraine-to-be-Presented-at-the-American-Headache-Society-s-65th-Annual-Scientific-Me.html

    GLOBENEWSWIRE
    15 Jun 2023
    Share Share
    Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101
    Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101

    https://www.globenewswire.com/news-release/2023/05/18/2672216/0/en/Satsuma-Pharmaceuticals-Announces-FDA-Acceptance-of-505-b-2-NDA-for-STS101-a-Novel-and-Investigational-Dihydroergotamine-DHE-Nasal-Powder-Product-for-the-Acute-Treatment-of-Migrain.html

    GLOBENEWSWIRE
    18 May 2023
    Share Share
    Satsuma Announces 3Abstracts Accepted at The 75th American Academy Neurology
    Satsuma Announces 3Abstracts Accepted at The 75th American Academy Neurology

    https://www.globenewswire.com/news-release/2023/04/21/2651873/0/en/Satsuma-Pharmaceuticals-Announces-Three-Abstracts-Accepted-at-The-75th-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    21 Apr 2023
    Share Share
    SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General Louisiana
    SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General Louisiana

    https://www.businesswire.com/news/home/20230421005376/en

    BUSINESSWIRE
    21 Apr 2023
    Share Share
    With skin in the game, Satsuma's partner offers buyout
    With skin in the game, Satsuma's partner offers buyout

    https://www.fiercebiotech.com/biotech/skin-game-satsumas-partner-offers-buy-ailing-biotech-get-migraine-spray-market

    James Waldron FIERCE BIOTECH
    17 Apr 2023
    Share Share
    Satsuma peels off staff, cutting head count by 36% to save cash
    Satsuma peels off staff, cutting head count by 36% to save cash

    https://www.fiercebiotech.com/biotech/satsuma-peels-staff-cutting-headcount-36-save-cash-while-searching-deal

    Nick Paul Taylor FIERCE BIOTECH
    29 Mar 2023
    Share Share
    Satsuma Reports Fourth Quarter and Full Year 2022 Financial Results
    Satsuma Reports Fourth Quarter and Full Year 2022 Financial Results

    https://www.globenewswire.com/news-release/2023/03/28/2636198/0/en/Satsuma-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Business-Highlights.html

    GLOBENEWSWIRE
    28 Mar 2023
    Share Share
    Satsuma to Participate in the Virtual SVB Securities Global Biopharma Conference
    Satsuma to Participate in the Virtual SVB Securities Global Biopharma Conference

    https://www.globenewswire.com/news-release/2023/02/02/2600405/0/en/Satsuma-Pharmaceuticals-to-Participate-in-the-Virtual-SVB-Securities-Global-Biopharma-Conference.html

    GLOBENEWSWIRE
    02 Feb 2023
    Share Share
    Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
    Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

    https://www.globenewswire.com/news-release/2022/12/20/2577188/0/en/Satsuma-Pharmaceuticals-Provides-STS101-Development-Program-and-Corporate-Update.html

    GLOBENEWSWIRE
    20 Dec 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search